2026 Childhood Vaccine Schedule Updates: What’s in Effect and What Could Change
By Jason Peterson, RPh; Beckie Fenrick, PharmD; and Long Tran, PharmD As families prepare for a new school year, immunization records are back […]
Articles
Biosimilars: Is Your Plan Capturing the Value?
By Beckie Fenrick, PharmD, MBA, Chief Pharmacy Officer at Navion Every major PBM has biosimilars on formulary. That doesn’t mean your groups are saving
Your Groups Are Overpaying on Pharmacy. The Renewal Math Is Hiding It.
By Lad Williamson, Vice President of Business Development at Navion Every year, the same meeting happens. The renewal comes in higher than
Migraine Medications and Rising Pharmacy Spend: What Plan Sponsors Need to Know
By Long Tran, PharmD; Beckie Fenrick, PharmD; and Jason Peterson, RPh Migraine treatment has changed significantly over the past decade. What
Q2 2026 Drug Updates: New FDA Approvals, Generics and Biosimilars to Watch
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh In Q2 2026, the FDA approved several
Your PBM Contract Has Fine Print. The Fine Print Is Where the Money Is.
By Giorgio Vescera, Vice President of Underwriting and Analytics at Navion Most PBM contracts are won on the pricing grid. That
What Plan Sponsors Need to Know About HIV Treatment, PrEP and Pharmacy Costs
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh HIV prevention and treatment options are expanding
